908 Devices Inc. (MASS)
| Market Cap | 526.18M +71.3% |
| Revenue (ttm) | 60.84M +13.3% |
| Net Income | -34.66M |
| EPS | -0.94 |
| Shares Out | 41.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,792 |
| Open | 12.46 |
| Previous Close | 12.36 |
| Day's Range | 12.30 - 12.93 |
| 52-Week Range | 5.03 - 13.35 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 13.38 (+5.11%) |
| Earnings Date | Nov 10, 2026 |
About MASS
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MASS stock is "Strong Buy." The 12-month stock price target is $13.38, which is an increase of 5.11% from the latest price.
News
908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices initiated with a Buy at Canaccord
Canaccord initiated coverage of 908 Devices (MASS) with a Buy rating and $13.50 price target The company develops handheld and tabletop chemical analysis equipment that lets personnel detect, identify...
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Transcript: 17th Annual Midwest IDEAS Conference
Focused on handheld chemical detection, the company reported 23% revenue growth and improved profitability, driven by macro tailwinds and a diversified customer base. Product innovation, recurring revenue expansion, and regulatory shifts support durable growth, with strong financials and a robust pipeline of opportunities.
908 Devices Slides: 17th Annual Midwest IDEAS Conference
908 Devices has posted slides in relation to its latest quarterly earnings report, which was published on August 26, 2026.
908 Devices price target raised to $12 from $10 at Stifel
Stifel raised the firm’s price target on 908 Devices (MASS) to $12 from $10 and keeps a Buy rating on the shares after a Q2 beat and an upward tweak…
908 Devices price target raised to $13 from $11 at Roth Capital
Roth Capital raised the firm’s price target on 908 Devices (MASS) to $13 from $11 and keeps a Buy rating on the shares. The firm cites the company’s Q2 revenue…
908 Devices Transcript: Canaccord Genuity's 46th Annual Growth Conference
Transitioned to focus on handheld chemical detection for public safety and defense, leveraging new products and acquisitions to expand in the U.S. and Europe. Legislative changes and grant funding are driving adoption, while cloud connectivity and manufacturing scale support growth. Next-gen devices and drone integration are key future opportunities.
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 23% year-over-year to $16.1 million, driven by strong handheld device sales and recurring revenue growth. Integration of NIRLab and a $6 million ProtectIR order support raised full-year guidance, with adjusted EBITDA loss improving by over 50%.
908 Devices Earnings release: Q2 2026
908 Devices released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
908 Devices Slides: Q2 2026
908 Devices has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
908 Devices Quarterly report: Q2 2026
908 Devices has published its Q2 2026 quarterly earnings report on August 11, 2026.
908 Devices reports Q2 EPS (32c), consensus (14c)
Reports Q2 revenue $16.1M, consensus $15.37M. “We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ag...
908 Devices narrows FY26 revenue view to $68M-$70M from $67M-$70M
Consensus $68.59M
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tec...
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices initiated with a Buy at Roth Capital
Roth Capital initiated coverage of 908 Devices (MASS) with a Buy rating and $11 price target The firm views 908 as a “high-quality, pure-play” handheld chemical detection company that provides…
908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Transcript: 16th Annual East Coast IDEAS Conference
The company has transformed into a focused provider of handheld chemical detection devices, achieving strong revenue growth, improved margins, and a diversified customer base. Recent acquisitions, product innovation, and a shift toward recurring software revenue position it for continued expansion and profitability.
908 Devices Slides: 16th Annual East Coast IDEAS Conference
908 Devices has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices price target raised to $10 from $8 at Stifel
Stifel raised the firm’s price target on 908 Devices (MASS) to $10 from $8 and keeps a Buy rating on the shares.
908 Devices completes acquisition of NIRLAB AG
908 Devices (MASS) announced that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared...